[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356143-105":59,"doc-detail-356143-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sensitivity-to-endocrine-therapy-index-predicts-benefit-from-weekly-adjuvant-paclitaxel-for-hormone-receptorpositive-breast-cancer-in-the-geicam9906-trial","Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial","","Sensitivity to endocrine therapy (SETER/PR) low transcriptional activity was independently validated as a predictor of benefit from dose-dense paclitaxel in hormone receptor–positive breast cancer. A blinded prospective–retrospective biomarker analysis was conducted within the GEICAM/9906 trial, comparing adjuvant FEC followed by weekly paclitaxel versus six cycles of FEC. SETER/PR index was measured using a prespecified cut point (\u003C0.75). The primary endpoint was distant recurrence–free interval (DRFI), with overall and breast cancer–specific survival as secondary endpoints.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sensitivity-to-endocrine-therapy-index-predicts-benefit-from-weekly-adjuvant-paclitaxel-for-hormone-receptorpositive-breast-cancer-in-the-geicam9906-trial/356143/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sensitivity-to-endocrine-therapy-index-predicts-benefit-from-weekly-adjuvant-paclitaxel-for-hormone-receptorpositive-breast-cancer-in-the-geicam9906-trial/356143.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this study regarding the SETER/PR index?","Question",{"text":112,"@type":113},"To validate that low endocrine transcriptional activity measured by the SETER/PR index predicts benefit from dose-dense paclitaxel chemotherapy in hormone receptor–positive breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the GEICAM/9906 trial structured for this biomarker analysis?",{"text":117,"@type":113},"The analysis used GEICAM/9906, comparing adjuvant FEC followed by weekly paclitaxel versus six cycles of FEC in lymph node–positive breast cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about patients with low versus high SETER/PR index?",{"text":121,"@type":113},"A low SETER/PR index (\u003C0.75) identified 92 tumors and showed a significant interaction with treatment on DRFI; FEC + paclitaxel significantly improved DRFI, while no treatment benefit was observed for SETER/PR ≥0.75.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356143,1790212080,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial  \nMiguel Martn1,2, Alvaro Rodriguez-Lescure1,3, Cristina Reboredo1,4, Eveline Chen5,  \nManuel Ruiz-Borrego1,6, Ana Santaballa Bertran1,7, Cesar A. Rodr´ıguez1,8, Noelia Martinez-Jañez1,9, Emilio Alba1,10,11,12, Kevin Tran5, Ignacio Pelaez Fernandez1,13, Isabel ´Alvarez1,14, Miguel A. Segu1,15, Alberto de la Cruz1,16, Vicente Valero5, Antonio Antn-Torres1,17, Raquel Andrs1,18, Kepa Amillano1,19, Jos J. Ponce-Lorenzo1,20, Severina Dominguez Fernandez1,21, Jesus Herranz1, Raul Rincon1, Rosala Caballero1, Angel Guerrero-Zotano1,22, Federico Rojo1,23, and W. Fraser Symmans5  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: To independently validate that low endocrine transcriptional activity measured by the sensitivity to endocrine therapy (SETER/PR) index in hormone receptor–positive (HR+) breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective–retrospective biomarker study.\u003Cbr>Experimental Design: We conducted a blinded, prospective– retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel (P) versus six cycles of FEC in lymph node–positive breast cancer. The SETER/PR index was measured in all available HR+/ HER2 􀀁 tumor RNA samples using a prespecified cut point (\u003C0.75) . The primary endpoint was the distant recurrence–free interval (DRFI); secondary endpoints were overall survival (OS) and breast cancer–specific survival (BCSS) .\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: Of 647 HR+/HER2 􀀁 tumors, 567 (87.6%) passed assay quality control (279 FEC + P; 288 FEC). A low SETER/PR index was identified in 92 tumors (16.2%). There was a significant interaction between SETER/PR status and treatment on DRFI (P ¼ 0.046). Among patients with a low SETER/PR index, FEC + P significantly improved DRFI [hazard ratio (HR), 0.46; 95% confidence interval (CI), 0.22–0.95; P ¼ 0.035], with similar results after adjustment (HR, 0.48; 95% CI, 0.24–1; P ¼ 0.049). No treatment benefit was observed for SETER/PR ≥0.75 (HR, 1.02; 95% CI, 0.70–1.47; P ¼ 0.931). Differences in OS and BCSS did not reach significance.\u003Cbr>Conclusions: Low endocrine transcriptional activity predicts benefit from adding weekly paclitaxel to anthracycline-based adjuvant chemotherapy in HR+/HER2 􀀁 breast cancer. These findings independently validate the SETER/PR index as a predictive biomarker for paclitaxel-based chemotherapy and support its potential role in guiding regimen selection. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nThe recent meta-analysis by the Early Breast Cancer Trials Collaborative Group (EBCTCG) demonstrated that improvements in  \n1GEICAM, Sp","cbCaioA6g2A55UTS","https://ap.wps.com/l/cbCaioA6g2A55UTS","pdf",1957547,"English","# Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the purpose of this study regarding the SETER/PR index?\",\"answer\":\"To validate that low endocrine transcriptional activity measured by the SETER/PR index predicts benefit from dose-dense paclitaxel chemotherapy in hormone receptor–positive breast cancer.\"},{\"question\":\"How was the GEICAM/9906 trial structured for this biomarker analysis?\",\"answer\":\"The analysis used GEICAM/9906, comparing adjuvant FEC followed by weekly paclitaxel versus six cycles of FEC in lymph node–positive breast cancer.\"},{\"question\":\"What were the key findings about patients with low versus high SETER/PR index?\",\"answer\":\"A low SETER/PR index (\\u003c0.75) identified 92 tumors and showed a significant interaction with treatment on DRFI; FEC + paclitaxel significantly improved DRFI, while no treatment benefit was observed for SETER/PR ≥0.75.\"}]","Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial | PDF",1790123626,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29a34d9cd0250a5974523bd76d77d4de.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ecb1daecef67e1d475102afc5984027.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5394650c8239ca122e82db89ff55215a.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0cb7478ea325ab86d7e44c706bf313a.webp",980,1311]